spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  MEK inhibitor 

 HSMN NewsFeed - 17 Jun 2019
Pfizer to Acquire Array BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2018
Avella Selected by Array BioPharma Inc. to distribute BRAFTOVI(TM) (encorafenib) and MEKTOVI(R) (binimetinib)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 12 Feb 2018
ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2017
Biocept Launches Liquid Biopsy Test for NRAS Mutations
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 31 May 2017
Array BioPharma And Ono Pharmaceutical Co., Ltd. Announce A License, Development And Commercialization Partnership For Two Novel Oncology Compounds, Binimetinib And Encorafenib
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2016
Array BioPharma Announces Appointment Of Jason Haddock As Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Oct 2015
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma
Biopharmaceuticals Oncology Dermatology
 HSMN NewsFeed - 22 Jul 2015
AstraZeneca Provides Update On Selumetinib In Uveal Melanoma
Biopharmaceuticals Oncology Ophthalmology
 HSMN NewsFeed - 19 Feb 2015
FDA Grants Genentech’s Cobimetinib Priority Review for Use in Combination with Zelboraf (Vemurafenib) in Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Jul 2014
Genentech’s Investigational Medicine Cobimetinib, Used in Combination with Zelboraf(R) (Vemurafenib), Helped People with Advanced Melanoma Live Significantly Longer Without Their Disease Worsening
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2012
Array BioPharma Names Howard Holden, Ph.D., Vice President of Regulatory Affairs and Quality Assurance
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 3

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 3 additional stories matching:
MEK inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.